New bordatella vaccine from Zoetis
Zoetis has launched Versican Plus Bp Oral, a new vaccine to tackle Bordetella bronchiseptica, a primary component of the canine infectious respiratory disease complex (CIRDC).
The new vaccine, which is also the first in Europe to be administered orally, offers increased comfort for dogs and a more pleasant consultation experience for owners and vets. It has a 12-month duration of immunity.
Dr. Eileen Ball, global veterinary medical lead for companion animal infectious diseases for Zoetis, says:
‘Versican Plus Bb Oral provides robust protection along with an innovative and smooth means of administration. The new oral delivery brings a more positive experience for dogs, owners and vets. We expect this new option for vaccination will lead to an increase in recommendations for Bordetella prevention, better vaccination compliance, and ultimately a healthier dog population.’
Dr Ball says that nearly all dogs are at risk from CIRDC and Bordetella is a common but preventable pathogen:
‘Adding Versican Plus Bb Oral to vaccination protocols offers CIRDC protection for dogs. Vets can propose this new vaccination to pet owners at an annual wellness visit in the knowledge that they will be creating a less stressful experience for the pet and owner,’ she adds.
Zoetis has set up The European Canine Infectious Respiratory Disease Advisory Board – made up of veterinary specialists from across Europe – to provide guidance and advice on the product’s launch.